SCHEMBL17134702

SCHEMBL17134702

Cc1ccc(Cl)cc1Nc1c(C(=O)N2CCC(c3ccccc3)CC2)cnc(S(N)(=O)=O)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ CCKBR P32239 1/20 0.46
▸ AVPR1A P37288 1/20 0.44
▸ SPR P35270 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ FASN P49327 4/20 0.41
▸ EGLN1 Q9GZT9 2/20 0.40
▸ F11 P03951 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ PRSS12 P56730 1/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17135011 0.85 SPR (0.46) CCKBRAVPR1ASPRMAPTCA12
SCHEMBL17134624 0.85 FASN (0.42) CCKBRAVPR1AMAPTFASNEGLN1
SCHEMBL17184249 0.85 FASN (0.41) MAPTSMN1; SMN2CA12CA1CA2
SCHEMBL17292884 0.84 DRD4 (0.44) KMT2ACCKBRAVPR1ASPRMAPT
SCHEMBL17134796 0.83 FASN (0.38) KMT2AMEN1MAPTSMN1; SMN2FASN
SCHEMBL17134635 0.83 FASN (0.42) FASNPRSS12
SCHEMBL17134706 0.83 FASN (0.42) CA2FASNEGLN1
SCHEMBL17134765 0.82 TRPC6 (0.41) CCKBRAVPR1AFASNEGLN1PRSS12
SCHEMBL17134832 0.82 FASN (0.43) MAPTSMN1; SMN2FASNEGLN1PRSS12
SCHEMBL17135043 0.81 CCKBR (0.45) KMT2AMEN1CCKBRAVPR1ASPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR KMT2A 392/4885MEN1 1212/4885CCKBR 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback